We will rely on you to help lend your voice and support the biotechnology industry.
Bringing new treatments to patients, support public policies that promote innovation, improve patient access.
BIO International ConventionJune 3-6, 2019
BIO World Congress on Industrial Biotechnology and Ag TechJuly 8-11, 2019
BIO Industry Analysis Reports >>
Save. Advocate. Connect. Join Us.
A listing of all BIO members and subsidiaries.
February 11 - 12, 2019 | New York, New York
Amanda Haidet-Phillips serves as Scientific Portfolio Director for the Muscular Dystrophy Association (MDA) where she leads the strategic management of research grants and investments focused on Amyotrophic Lateral Sclerosis, Spinal Muscular Atrophy, Charcot-Marie-Tooth Disease, and Myasthenia Gravis. Amanda also provides scientific expertise and leadership for MDA through interactions with biotech and pharma companies, patient-advocacy groups, donors, partners, and other stakeholders in the neuromuscular disease space. Prior to joining MDA, Amanda conducted research at Johns Hopkins University seeking to understand the causes of ALS and develop new therapeutic approaches for the disease. Amanda received her Ph.D from The Ohio State University where she helped to develop gene therapies for neuromuscular disease. Amanda has co-authored 18 peer-reviewed manuscripts and serves on external committees and advisory boards within the neuromuscular disease field.
This speaker's sessions: